General anaesthesia drugs are used to induce a sedative state in patients who are to go through a surgical procedure. Further, general anaesthesia drugs can be segmented into two sub-segments based on the route of administration, general anaesthesia drugs administered through the intravenous route is categorized as an intravenous anaesthetic and general anaesthesia drugs administered through inhalation is categorized as an inhalation anaesthetic. It is a must to maintain the sedative stage in the patient during a surgical procedure, usually for this stage, inhalation anaesthesia are administered to the patients; while for the induction stage, intravenous general anaesthesia s is preferred.
Market Value and Forecast
In terms of value, the global general anaesthesia drugs market is estimated to expand at a CAGR of 3.8% during the forecast period. Moreover, global general anaesthesia drugs markets value is expected to increase to US$ 5,549.7 Mn by 2025 end.
Growth of the global general anaesthesia drugs market is mainly driven by rising incidences of cardiovascular diseases, chronic respiratory diseases, craniomaxillofacial surgeries and accidents. However, lack of a single effective drug for all type of surgeries, side effects and complications during the surgical procedure, lack of skilled anaesthesiologists and certified registered nurse anaesthesiologists, inadequate insurance coverage, coupled with high prices of these drugs are restraining market growth.
In addition, side effects such as nausea, vomiting, allergy, sleep apnea and complications during surgical procedures are anticipated to drive the demand for improvement in the quality of drugs.
Segmentation by Product
The global general anaesthesia drugs market is segmented on the basis of molecule/product. In terms of value, the propofol segment is estimated to account for over 29.8% share to the global general anaesthesia drugs market by 2015 end and is expected to remain dominant during the forecast period.
The global general anaesthesia drugs market has been segmented into seven major regions, namely: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan (APEJ), Japan, and Middle East & Africa. In terms of value, North America is estimated to dominate the market with 31.0% share of the overall general anaesthesia drugs market by 2015 end. APEJ is estimated to be the fastest-growing market, registering a CAGR of 5.2% in terms of value, over the forecast period.
Some of the key players identified in the global general anaesthesia drugs market report include Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, and Hospira Inc. These players are focused on developing new drugs with minimum side effects and maximum efficacy to seize the maximum of the global market share.